Citable filing context

IQV filing events and research context

Server-rendered

IQV's research view summarizes recent SEC filing context, starting with mda_quarterly from May 5, 2026.

IQV filing events and research context
FiledItemContext
May 5, 2026mda_quarterlyIQVIA reported total revenues of $4.15 billion for the first quarter of 2026, an 8.4% increase over the same period in 2025. This growth was driven by a 6.0% increase in constant currency revenue, with Commercial Solutions contributing $1.75 billion and Research & Development Solutions contributing $2.40 billion. The company recently reorganized its reporting structure, consolidating Contract Sales & Medical Solutions into the renamed Commercial Solutions segment and shifting certain Real-World offerings into the Research & Development Solutions segment. Operating performance remains robust, with income from operations rising to $514 million from $496 million in the prior year. The Research & Development Solutions segment maintains a strong contracted backlog of $34.2 billion, with approximately $8.9 billion expected to convert to revenue within the next twelve months. Liquidity remains stable, with $1.95 billion in cash and cash equivalents. During the quarter, IQVIA utilized a new $650 million Term Loan due 2027 to retire €550 million of 1.750% senior notes. The company continues to execute its capital allocation strategy, repurchasing $552 million of common stock during the quarter. Management expects ongoing restructuring efforts to continue through 2027 to streamline operations and integrate recent acquisitions.
Feb 17, 2026businessIQVIA operates within the biopharmaceutical and healthcare industries through its Research & Development (R&D) and Commercial Solutions segments, providing clinical trial management—including Phase I facilities—and drug marketing and sales services. The company pursues growth through strategic acquisitions and expansion into the broader healthcare market. A primary strategic risk is the emergence of generative AI, machine learning, and Real World Evidence, which may allow clients to internalize clinical development tasks or reduce demand for IQVIA’s analytics. Financial stability is impacted by substantial indebtedness subject to restrictive covenants and significant exposure to foreign currency volatility. Regulatory risks include the Inflation Reduction Act’s drug pricing negotiations, FCPA compliance across global operations, and evolving data privacy mandates. Furthermore, the company is susceptible to revenue loss from client consolidation, where mergers among biopharma firms eliminate overlapping services. Operational viability relies on the ability to recruit clinical investigators and patients and attract specialized talent in AI and clinical research. These factors, combined with the threat of lower-cost generic competition affecting client R&D budgets, create a volatile operating environment.
Feb 17, 2026mdaIQVIA reported 2025 revenues of $16.31 billion, a 5.9% increase over 2024, despite macroeconomic headwinds that slowed customer decision-making. Growth was led by the Technology & Analytics Solutions segment, which grew 7.6% via Real-World and information services, and the Research & Development Solutions segment, which grew 4.3% through clinical services volume, partially offsetting a decline in COVID-19 related work. The company maintains a significant pipeline with total remaining performance obligations of $34.2 billion, including a $32.7 billion contracted backlog in Research & Development Solutions. Effective January 1, 2026, IQVIA will reorganize its reporting segments, merging Contract Sales & Medical Solutions into a new Commercial Solutions segment. Liquidity remains stable with $1.98 billion in cash and $15.8 billion in total indebtedness. Capital allocation focused on growth and shareholder returns, with $1.71 billion invested in strategic acquisitions and $1.24 billion used for share repurchases in 2025. The Board further expanded the repurchase program by $2 billion in February 2025. Key operational risks include foreign currency volatility, as 30% of revenues are non-USD, and ongoing restructuring costs to streamline global operations and reduce overcapacity.

Source: SEC EDGAR filing text and events; period May 5, 2026; filed May 5, 2026.

Continue research

Keep researching IQV

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →